2az9: Difference between revisions

New page: left|200px<br /> <applet load="2az9" size="450" color="white" frame="true" align="right" spinBox="true" caption="2az9, resolution 2.50Å" /> '''HIV-1 Protease NL4-...
 
No edit summary
Line 1: Line 1:
[[Image:2az9.gif|left|200px]]<br />
[[Image:2az9.gif|left|200px]]<br /><applet load="2az9" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2az9" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2az9, resolution 2.50&Aring;" />
caption="2az9, resolution 2.50&Aring;" />
'''HIV-1 Protease NL4-3 1X mutant'''<br />
'''HIV-1 Protease NL4-3 1X mutant'''<br />


==Overview==
==Overview==
The development of resistance to anti-retroviral drugs targeted against, HIV is an increasing clinical problem in the treatment of HIV-1-infected, individuals. Many patients develop drug-resistant strains of the virus, after treatment with inhibitor cocktails (HAART therapy), which include, multiple protease inhibitors. Therefore, it is imperative that we, understand the mechanisms by which the viral proteins, in particular HIV-1, protease, develop resistance. We have determined the three-dimensional, structure of HIV-1 protease NL4-3 in complex with the potent protease, inhibitor TL-3 at 2.0 A resolution. We have also obtained the crystal, structures of three mutant forms of NL4-3 protease containing one (V82A), three (V82A, M46I, F53L) and six (V82A, M46I, F53L, V77I, L24I, L63P), point mutations in complex with TL-3. The three protease mutants arose, sequentially under ex vivo selective pressure in the presence of TL-3, and, exhibit fourfold, 11-fold, and 30-fold resistance to TL-3, respectively., This series of protease crystal structures offers insights into the, biochemical and structural mechanisms by which the enzyme can overcome, inhibition by TL-3 while recovering some of its native catalytic activity.
The development of resistance to anti-retroviral drugs targeted against HIV is an increasing clinical problem in the treatment of HIV-1-infected individuals. Many patients develop drug-resistant strains of the virus after treatment with inhibitor cocktails (HAART therapy), which include multiple protease inhibitors. Therefore, it is imperative that we understand the mechanisms by which the viral proteins, in particular HIV-1 protease, develop resistance. We have determined the three-dimensional structure of HIV-1 protease NL4-3 in complex with the potent protease inhibitor TL-3 at 2.0 A resolution. We have also obtained the crystal structures of three mutant forms of NL4-3 protease containing one (V82A), three (V82A, M46I, F53L) and six (V82A, M46I, F53L, V77I, L24I, L63P) point mutations in complex with TL-3. The three protease mutants arose sequentially under ex vivo selective pressure in the presence of TL-3, and exhibit fourfold, 11-fold, and 30-fold resistance to TL-3, respectively. This series of protease crystal structures offers insights into the biochemical and structural mechanisms by which the enzyme can overcome inhibition by TL-3 while recovering some of its native catalytic activity.


==About this Structure==
==About this Structure==
2AZ9 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2AZ9 OCA].  
2AZ9 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2AZ9 OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Human immunodeficiency virus 1]]
[[Category: Human immunodeficiency virus 1]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Elder, J.H.]]
[[Category: Elder, J H.]]
[[Category: Heaslet, H.]]
[[Category: Heaslet, H.]]
[[Category: Kutilek, V.]]
[[Category: Kutilek, V.]]
[[Category: Lin, Y-C.]]
[[Category: Lin, Y-C.]]
[[Category: Morris, G.M.]]
[[Category: Morris, G M.]]
[[Category: Stout, C.D.]]
[[Category: Stout, C D.]]
[[Category: Torbett, B.E.]]
[[Category: Torbett, B E.]]
[[Category: hiv; protease; inhibitor; tl-3; v82a]]
[[Category: hiv; protease; inhibitor; tl-3; v82a]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov  8 14:42:18 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:32:33 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA